Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Wednesday. The firm currently has a $5.00 price objective on the biopharmaceutical company’s stock. Zacks Investment Research’s price target points to a potential upside of 10.86% from the company’s previous close.
According to Zacks, “Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel. “
A number of other equities analysts have also weighed in on GLMD. Maxim Group reiterated a “buy” rating and set a $9.00 target price (down previously from $24.00) on shares of Galmed Pharmaceuticals in a research report on Monday, August 1st. HC Wainwright restated a “buy” rating on shares of Galmed Pharmaceuticals in a research report on Thursday, June 30th. Roth Capital restated a “buy” rating and issued a $6.00 price objective on shares of Galmed Pharmaceuticals in a research report on Wednesday, July 6th. Finally, FBR & Co set a $20.00 price objective on shares of Galmed Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, August 5th. Five analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and an average price target of $12.40.
Galmed Pharmaceuticals (NASDAQ:GLMD) opened at 4.51 on Wednesday. The firm’s market capitalization is $50.07 million. The company’s 50-day moving average is $4.16 and its 200-day moving average is $4.71. Galmed Pharmaceuticals has a 52-week low of $3.50 and a 52-week high of $10.20.
Galmed Pharmaceuticals (NASDAQ:GLMD) last issued its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by $0.04. Analysts forecast that Galmed Pharmaceuticals will post ($1.51) EPS for the current fiscal year.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Galmed Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.